CARM1 and diffuse large B-cell lymphoma: Previous studies revealed an oncogenic activity of the overexpressed PRMTs in distinct hematological malignancies, including AML (CARM1 [61, 62], PRMT5 [63]), diffuse-large B cell lymphoma (DLBCL) (PRMT5 [64]), and B-cell leukemia/lymphoma (PRMT5 [65, 66]).